Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death  by Ringdén, O. et al.
highly DC2 selective. Selective clones were DNA sequenced re-
vealing the random peptide insert. A 1-way MLR was performed
with varying dilution of each ampliﬁed DC2 speciﬁc phage to
demonstrate the cellular affects on allogeneic T-cell proliferation.
Results: Plaque assays from the monocyte adsorbed or non-ad-
sorbed linear random peptide library after the three rounds of
panning revealed two consensus sequences in 76 of the 78 (97%)
isolated clones that were DC2 selective and one sequence found
twice (3%) that was non-DC2 selective. The employed circular
random peptide library revealed no DC2 selective sequences from
15 isolated in clones from the monocyte adsorbed and non-ad-
sorbed plaque assays. Preliminary MLR data shows a 35 % reduc-
tion in allogeneic T-cell proliferation with the DC2 speciﬁc phage
compared to control phage. Conclusions: Data shows that phage
display technology can result in isolating highly speciﬁc DC2
peptides from a library of 10,000 different phage clones. Prelimi-
nary data suggests that binding DC2 speciﬁc peptides may inhibit
the function of these immunoregulatory cells, leading to enhanced
anti-tumor affect of the transplanted donor graft product by shift-
ing it towards an activated Th1 immune response.
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TREATMENT WITH GRANULOCYTE COLONY-STIMULATING FACTOR
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Purpose: Granulocyte colony-stimulating factor (G-CSF) is
given after bone marrow transplantation (BMT) to shorten the
neutropenic phase. Its effects have not been evaluated in a large
patient population. Patients and Methods: We studied 1789 pa-
tients with acute leukaemia receiving BMT and 434 patients re-
ceiving peripheral blood stem cells (PBSC) from HLA-identical
siblings from 1992 to 2002 and reported the ﬁndings to the Eu-
ropean Group for Blood and Marrow Transplantation (EBMT).
Among the BMT and PBSC patients, 501 (28%) and 175 (40%),
respectively, were treated with G-CSF during the ﬁrst 14 days after
the transplant. The outcome variables were entered in a Cox
proportional hazard model. Results: BMT and PBSC patients
treated with G-CSF had a faster engraftment of absolute neutro-
phils 0.5  109/l (p  0.01), but platelet engraftment (50 
109/l) was slower (p  0.001). In the BMT patients, acute graft-
versus-host disease (GVHD) grades II-IV was 50  5% (95%
conﬁdence interval) in the G-CSF group vs. 39  3% in the
controls (relative risk (RR) 1.33, p  0.007, in the multivariate
analysis). The incidence of chronic GVHD was also increased (RR
0.29, p  0.03).
G-CSF was associated with an increase in transplant-related
mortality (TRM) (RR 1.73, p  0.00016), had no effect on relapse,
but reduced the survival (RR 1.7, p  0.0001) and leukaemia-free
survival rates (LFS) (RR 1.55, p  0.0003). No such effects of
G-CSF were seen in patients receiving PBSC. Conclusion: After
BMT, platelet engraftment was delayed, and GVHD and TRM
were increased. Survival and LFS were reduced. This suggests that
G-CSF should not be given shortly after BMT.
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SUBEROYLANILIDE HYDROXAMIC ACID REDUCES ACUTE GRAFT-VER-
SUS-HOST DISEASE AND PRESERVES GRAFT-VERSUS-LEUKEMIA EF-
FECT BY INHIBITING HISTONE DEACETYLATION
Reddy, P.1, Maeda, Y.1, Hotary, K.1, Dinarello, C.A.2, Ferrara, J.L.1 1.
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;
2. University of Colorado Medical Center, Denver, CO
Pro-inﬂammatory cytokines and the loss of gastrointestinal tract
integrity contribute to acute graft-versus-host disease (GVHD)
whereas the donor cytotoxic responses are critical for graft-versus-
leukemia (GVL) preservation. Suberoylanilide hydroxamic acid
(SAHA) is an anti-tumor agent that inhibits the activity of histone
deacetylases (HDAC) and reduces the production of proinﬂamma-
tory cytokines. Using a well characterized allogeneic murine BMT
model B6 (H-2b) 3 B6D2F1 (H-2b/d) we studied the effects of
HDAC inhibition by SAHA on acute GVHD. Recipients were
transplanted with 2x10 6 donor T and 5x106 BM cells after13 GY
TBI. Intra-peritoneal injections of 35 mg/kg/day of SAHA from
days 3 to day 7 increased histone H3 acetylation in splenocytes
harvested 7 days after BMT, conﬁrming the inhibition of HDAC
enzymes. SAHA treatment signiﬁcantly reduced the serum levels of
pro-inﬂammatory cytokines such as TNF-a, IL-1	 and IFN-

(P  0.04) in the allogeneic recipients on day 7 after BMT.
Intracytoplasmic staining by ﬂow cytometry and RPA analysis of
the host splenocytes on day 7 conﬁrmed the decrease in the
cytokine protein and mRNA. SAHA signiﬁcantly improved the
survival (P 0.002) and reduced intestinal damage from GVHD of
the allogeneic recipients . However SAHA did not suppress the
donor T cell expansion in vivo and the proliferative and cytotoxic
responses to host antigens in vitro measured 7 and 14 days after
BMT. To test the effect of SAHA on GVL effects, recipients were
injected with lethal doses of P815 (H-2d) tumor cells at the time of
BMT. SAHA treatment resulted in signiﬁcantly improved leuke-
mia-free survival after allogeneic BMT (P  0.05) whereas all the
syngeneic BMT recipients of SAHA died of tumor ruling out
direct anti-tumor effects of SAHA. Furthermore SAHA increased
H3 acetylation in the splenocytes from both the syngeneic and
allogeneic leukemic recipients on day 7, conﬁrming that inhibi-
tion of HDAC enzymes alone is not sufﬁcient for leukemia free
survival in this system. We also tested the effect of SAHA in a
second allogeneic BMT model (BALB/c 3 B6), where it also
signiﬁcantly improved survival (P  0.001) and preserved GVL
effects when recipient mice were injected with lethal doses of EL-4
(H-2b) tumor (P  0.04). We conclude that HDAC inhibition
regulates acute GVHD in these models and suggest that this class
of pharmacologic agents may provide a novel strategy to reduce
GVHD while maintaining the beneﬁcial GVL effects.
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GANDS MIG AND IP-10 REDUCES THE SEVERITY OF IDIOPATHIC PNEU-
MONIA SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTA-
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Chemokines are important mediators in the development of
Idiopathic Pneumonia Syndrome (IPS), a major cause of mortality
after allogeneic (allo) stem cell transplantation (SCT). We hypoth-
esized, that recruitment of donor T cells to the lung is dependent,
at least in part, upon interactions between the chemokines MIG
and IP-10 and their receptor CXCR3. CXCR3 is expressed on
activated T cells; MIG and IP-10 can be induced in various cell
types by IFN
 alone or in combination with TNFa or IL-1ß. We
tested this hypothesis using an established murine SCT model
wherein lethally irradiated bm1 mice receive SCT from either
syngeneic (bm1) or allogeneic (B6Ly5.2) donors. MIG and IP-10
BAL levels were signiﬁcantly elevated in allo recipients compared
to syn controls at weeks 1 (MIG: 162.8  37.6 vs 0; IP-10: 41.1 
4.2 vs 0 pg/ml) and 4 (MIG: 153.5  41.7 vs 21.6  9.0; IP-10:
202.0  61.1 vs 3.8  0.9 pg/ml) and correlated with the inﬁltra-
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